First Drug: NIV-001

For our first neuroplasticity target, we have created a combinational drug for patients with chronic motor deficits from stroke (Chronic Stroke). Our three-drug combination (NIV-001) uses FDA approved drugs (approved for other indications) to boost the signaling between brain cells and target multiple mechanisms of action (or pathways) within the brain.